Build Your Own NGS Reference Standard: Try Our VariantFlex Configurator

NGS REFERENCE STANDARDS

Widest selection of high-performance multiplexed clinical genomics reference standards for tumor profiling, NIPT, cell-free DNA, and germline sequencing applications

INFECTIOUS DISEASE ASSAY TOOLS

Globally recognized serological and molecular quality controls and panels to validate, monitor, and ensure confidence in assay performance

IMMUNOASSAY REAGENTS

Readily available antibodies and immunoassay reagents to accelerate research and IVD assay development

Assay Developer OEM Solutions

Test Tube

SeraCare helps leading diagnostic assay developers build more robust assays, more quickly, with an array of highly customizable biological materials

NGS CONTROLS FOR CANCER PROFILING ASSAYS

SeraCare offers the broadest selection of reference materials with clinically relevant DNA and RNA variants applicable for NGS and PCR-based tests

CLINICAL NGS RESOURCE CENTER

Access helpful articles, white papers, and customer case studies on how to use SeraCare clinical genomics tools for validating and operationalizing your clinical assays

Validation eBook Cover

LOOKING FOR CLARITY ON NGS VALIDATION GUIDANCE?

Next-Generation Sequencing Assay Validation: A Practical Guide for the Clinical Genomics Laboratory

This practical guide walks through key considerations and guidelines to help you accelerate NGS assay validation for less money and greater confidence in results. Learn about:

  • Specific ways you can save time and money while thoroughly validating an NGS-based clinical genomics assay
  • Validation best practices from leading clinical genomics laboratories
  • How to navigate the many guidelines and requirements of the various authoritative bodies for clinical genomics testing

Download Our NGS Validation eBook

+

Fill out this form to download the eBook

TESTIMONIALS

+

  • SeraCare have been fantastic in helping us develop the plasma-based EQA schemes. Technically, that's very challenging to deliver as an EQA provider; it's not an easy sample type to be able to just get on-tap from any patient or biobank.
    - Dr. Sandi Deans, Director, UK NEQAS for Molecular Genetics and Molecular Pathology
  • We're basically getting more bang for our buck from [Seraseq] reference materials because they have more mutations represented within them.
    - Dr. Brian Haynes, Associate Director of Bioinformatics, Asuragen

Our Latest Blogs

Tips for Better EGFR Mutation Testing

Molecular testing of genomic alterations in the EGFR gene is critical to personalized treatment decisions for patients with advanced non-small cell lung cancer (NSCLC). However, the testing landscape is complex. Some mutations confer sensitivity, and others confer resistance to anti-EGFR targeted therapies.

If you’ve attended the AMP Annual Meeting over the years or seen any of the headlines it generates, you know how next-generation sequencing-based assays are becoming indispensable diagnostic, prognostic, and predictive tools for a growing number of disease states. But just as important as the newest biomarker or latest chemistry – but seemingly less headline-worthy – are NGS quality control and standardization.

 

Of the many fantastic posters presented at AMP’s Annual Meeting in San Antonio, two concerning NGS-based liquid biopsy assays stood out. Both presenters described how their organizations are working to reliably detect pathogenic variants at extremely low allele frequencies – efforts critical to the clinical adoption of NGS-based liquid biopsy assays.